Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-8862Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Schultheis, Michael | - |
| dc.contributor.author | Staubach, Petra | - |
| dc.contributor.author | Grabbe, Stephan | - |
| dc.contributor.author | Ruckes, Christian | - |
| dc.contributor.author | Stetbut, Esther von | - |
| dc.contributor.author | Kirschner, Uwe | - |
| dc.contributor.author | Matusiak, Łukasz | - |
| dc.contributor.author | Szepietowski, Jacek C. | - |
| dc.contributor.author | Nikolakis, Georgios | - |
| dc.date.accessioned | 2023-04-19T08:08:55Z | - |
| dc.date.available | 2023-04-19T08:08:55Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/8878 | - |
| dc.description.abstract | Background: Hidradenitis suppurativa is a chronic, inflammatory, burdensome skin disease where current first-line treatments are limited to topical and/or systemic antibiotics which cannot be applied for long-term disease management. Period B of the RELIEVE study analyzes whether LAight® therapy can sustain or even increase remission after a first topical antibiotic treatment cycle. Methods: The RELIEVE study was performed as a two-period multicenter randomized controlled trial with blinded assessment. For period A from week 0 to week 16, the 88 participating Hurley I and II patients were randomized to either a group receiving topical clindamycin 1% solution combined with 8 additional bi-weekly treatments with LAight® therapy (group TC + L) or a group which was treated with topical clindamycin 1% solution only (group TC). After 16 weeks, patients entered open-label period B and both groups were treated exclusively with LAight® therapy for an additional 16 weeks (8 sessions, group TC + L/L and group TC/L). Results: In total, 88 patients were enrolled in RELIEVE. Seventy-eight patients entered period B; 39 belonged to group TC + L/L and 39 to group TC/L. The IHS4-response at the start of period B was 62% (group TC + L/L) and 33% (group TC + L). During the 16 weeks of additional monotherapy with LAight, in both groups >90% of patients who responded to therapy in period A maintained their IHS4-response at week 32. IHS4 response rates continued to rise up to 79% of the TC + L/L group and up to 71% of the TC/L group during period B at week 32. Achievement of HiSCR and certain patient reported outcomes confirmed primary endpoint results. Conclusion: LAight® therapy is an effective approved therapy option for Hurley I and II HS that can be used continuously to maintain treatment success. During 16 weeks of follow-up in period B, over 90% of patients with response after period A maintained their treatment outcome, while more than 60% of prior nonresponders gained response. The fact that LAight® therapy can be applied continuously, is very effective and is well tolerated makes it a valuable treatment tool in the design of HS long- term treatment modalities. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | LAight® therapy is an effective treatment option to maintain long-term remission of Hurley I and II Hidradenitis Suppurativa: results from period B of RELIEVE, a multicenter randomized, controlled trial | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-8862 | - |
| jgu.type.contenttype | Scientific article | de |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Dermatology | de |
| jgu.journal.volume | 238 | de |
| jgu.journal.issue | 6 | de |
| jgu.pages.start | 1092 | de |
| jgu.pages.end | 1103 | de |
| jgu.publisher.year | 2022 | - |
| jgu.publisher.name | Karger | de |
| jgu.publisher.place | Basel ; Freibung [Breisgau] ; Paris ; London ; New York ; Bangalore ; Bankok ; Singapore ; Tokyo ; Sydney | de |
| jgu.publisher.issn | 1421-9832 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1159/000524739 | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| jgu.subject.dfg | Lebenswissenschaften | de |
| Appears in collections: | DFG-491381577-H | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | laight®_therapy_is_an_effecti-20230227091250479.pdf | 701.43 kB | Adobe PDF | View/Open | |
| laight®_therapy_is_an_effecti-20230227091303292.pptx | 419.1 kB | Microsoft Powerpoint XML | View/Open |